|
|
|
|
LEADER |
02047nmm a2200457 u 4500 |
001 |
EB001871969 |
003 |
EBX01000000000000001035340 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
190824 ||| eng |
100 |
1 |
|
|a Richardson, Paul G.
|
245 |
0 |
0 |
|a The evolving role of novel and next generation therapies in the management of multiple myeloma
|h Elektronische Ressource
|b part 2 of 2, relapse refractory multiple myeloma
|c Paul G. Richardson
|
246 |
3 |
1 |
|a Evolving role of novel and next generation therapies in the management of multiple myeloma. Part 2, Relapse refractory multiple myeloma
|
260 |
|
|
|a London
|b Henry Stewart Talks
|c 2019, 2019
|
300 |
|
|
|a 1 streaming video file (19 min.)
|b color, sound
|
505 |
0 |
|
|a T-cell therapy strategies for Multiple Myeloma -- Cell-based Myeloma vaccines -- Antibody-drug conjugates -- Continuing evolution of Multiple Myeloma treatment
|
653 |
|
|
|a Immunotherapy / trends
|
653 |
|
|
|a Multiple Myeloma / therapy
|
653 |
|
|
|a Bortezomib
|
653 |
|
|
|a Antibodies, Monoclonal / therapeutic use
|
653 |
|
|
|a Drug Discovery
|
653 |
|
|
|a isatuximab
|
653 |
|
|
|a Cancer Vaccines
|
653 |
|
|
|a Multiple Myeloma / drug therapy
|
653 |
|
|
|a Multiple Myeloma / immunology
|
653 |
|
|
|a Immunoconjugates / therapeutic use
|
653 |
|
|
|a Receptors, Antigen, T-Cell / therapeutic use
|
653 |
|
|
|a Multiple myeloma / Treatment
|
653 |
|
|
|a Antineoplastic Agents / therapeutic use
|
653 |
|
|
|a Antibody-drug conjugates
|
653 |
|
|
|a Recurrence
|
653 |
|
|
|a Antineoplastic agents
|
653 |
|
|
|a elotuzumab
|
653 |
|
|
|a T-Lymphocytes / immunology
|
653 |
|
|
|a Multiple myeloma / Chemotherapy
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b HST
|a Henry Stewart Talks
|
490 |
0 |
|
|a The biomedical & life sciences collection
|
500 |
|
|
|a Animated audio-visual presentation with synchronized narration. - Title from title frames. - Mode of access: World Wide Web
|
856 |
4 |
0 |
|u https://hstalks.com/bs/3990
|x Verlag
|z Streaming video file
|
082 |
0 |
|
|a 570
|